Data from BioTime’s OpRegen Program to Be Presented at AAO 2018

BioTime announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27-30, 2018, in Chicago, Illinois.

“We are delighted that the AAO has accepted our abstract for an oral presentation at the upcoming meeting,” Adi Mohanty, Co-Chief Executive Officer of BioTime, said in a company news release. “We look forward to sharing more data from the ongoing OpRegen clinical trial where we have observed signals that may suggest structural improvement in the retina.”